Inform Diagnostics announced that therapeutic drug monitoring is commercially available for Renflexis (infliximab-abda), a biosimilar of Remicade (infliximab).
Since launching the InformTx™ therapeutic drug monitoring (TDM) services in June 2016, the company has expanded its TDM testing to now eight biologic drugs that treat inflammatory bowel disease (IBD).
Inform Diagnostics uses laboratory-validated ELISA technology for TDM. Testing measures the level of the specified drug as well as patient-derived antibodies to the specified drug. Testing results are reported within five days. The company’s TDM report is unique in that it provides clinicians with quantitative test results, historical test data, and practice guidance from the most up-to-date peer-reviewed scientific literature.
